

AMENDMENTS TO THE CLAIMS

1. – 9. (Canceled)

10. (New) A method for the production of a viral particle, comprising:

culturing a cell in the presence of a virus or a sample suspected of containing a virus, said culturing being under conditions suitable for efficient viral replication, said cell having a targeted deletion in at least one of a protein kinase RNA-dependent (PKR) gene, a 2'-5'-linked oligoadenylate (2-5A) synthetase gene, or an Mx gene, wherein said cell has increased permissiveness to viral replication due to said targeted deletion; and
harvesting the viral particles produced.

11. (New) The method of claim 10, further comprising inactivating the viral particles produced for the production of a viral vaccine.

12. (New) The method of claim 11, wherein said method further comprises preparing a viral vaccine from said harvested viral particles.

13. (New) The method of claim 10, wherein said cell is deficient in interferon-mediated antiviral responses relative to a cell without the targeted deletion.

14. (New) The method of claim 10, further comprising determining viral titer prior to said harvesting.

15. (New) The method of claim 14, wherein the viral vaccine is suitable for human administration.

16. (New) The method of claim 14, further comprising formulating the viral particles produced thereby with a pharmaceutically acceptable carrier.

17. (New) The method of claim 10, wherein said deficient cell is a human cell.

18. **(New)** The method of claim 10, wherein said deficient cell is chosen from MRC-5, WI-38, Chang liver, U937, Vero, MRC-9, IMR-90, IMR-91, Lederle 130, MDCK, H9, CEM, or CD4-expressing HUT78.
19. **(New)** The method of claim 18, wherein said deficient cell is a MRC-5 or WI-38 or Vero cell.
20. **(New)** The method of claim 10, wherein said deficient cell is a U937 cell.
21. **(New)** The method of claim 10, wherein said donor virus is an attenuated virus.
22. **(New)** The method of claim 10, wherein said donor virus is a recombinant virus.
23. **(New)** The method of claim 10, wherein said donor virus is a human influenza virus.
24. **(New)** The method of claim 10, wherein said donor virus is a non-human virus.
25. **(New)** The method of claim 10, wherein said deficient cell is deficient in both PKR and 2-5A synthetase.
26. **(New)** A method for the production of a viral particle, comprising:
culturing a cell in the presence of a virus or a sample suspected of containing a virus, said culturing being under conditions suitable for viral replication, said cell having a targeted deletion in a protein kinase RNA-dependent (PKR) gene, wherein the cell has increased permissiveness to viral replication as a result of said targeted deletion; and
harvesting the viral particles produced.
27. **(New)** The method of claim 26, further comprising inactivating the viral particles produced.

28. **(New)** The method of claim 27, wherein said method further comprises preparing a viral vaccine from said harvested viral particles.

29. **(New)** The method of claim 26, wherein the cell has a further targeted deletion in a 2-5A synthetase gene.

30. **(New)** The method of claim 26, wherein the cell has a further targeted deletion in a Mx gene.

31. **(New)** The method of claim 26, further comprising determining viral titer prior to said harvesting step.

32. **(New)** The method of claim 26, wherein the viral vaccine is suitable for human administration.

33. **(New)** The method of claim 26, further comprising formulating the viral particles produced with a pharmaceutically acceptable carrier.

34. **(New)** The method of claim 26, wherein said deficient cell is a human cell.

35. **(New)** The method of claim 26, wherein said deficient cell is chosen from MRC-5, WI-38, Chang liver, U937, Vero, MRC-9, IMR-90, IMR-91, Lederle 130, MDCK, H9, CEM, or CD4-expressing HUT78.

36. **(New)** The method of claim 26, wherein said deficient cell is a MRC-5 or WI-38 or Vero cell.

37. **(New)** The method of claim 26, wherein said deficient cell is a U937 cell.

38. **(New)** The method of claim 26, wherein said donor virus is an attenuated virus.

39. **(New)** The method of claim 26, wherein said donor virus is a recombinant virus.

40. **(New)** The method of claim 26, wherein said donor virus is a human influenza virus.

41. **(New)** The method of claim 26, wherein said donor virus is a non-human virus.